Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2014 | 1 |
2022 | 1 |
2023 | 3 |
2024 | 2 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Empagliflozin in Patients with Chronic Kidney Disease.
N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4.
N Engl J Med. 2023.
PMID: 36331190
Free PMC article.
Clinical Trial.
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
EMPA-KIDNEY Collaborative Group.
EMPA-KIDNEY Collaborative Group.
Lancet Diabetes Endocrinol. 2024 Jan;12(1):51-60. doi: 10.1016/S2213-8587(23)00322-4. Epub 2023 Dec 4.
Lancet Diabetes Endocrinol. 2024.
PMID: 38061372
Free article.
Clinical Trial.
Item in Clipboard
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
EMPA-KIDNEY Collaborative Group.
EMPA-KIDNEY Collaborative Group.
Lancet Diabetes Endocrinol. 2024 Jan;12(1):39-50. doi: 10.1016/S2213-8587(23)00321-2. Epub 2023 Dec 4.
Lancet Diabetes Endocrinol. 2024.
PMID: 38061371
Free PMC article.
Clinical Trial.
Item in Clipboard
The IBV Valve trial: a multicenter, randomized, double-blind trial of endobronchial therapy for severe emphysema.
Wood DE, Nader DA, Springmeyer SC, Elstad MR, Coxson HO, Chan A, Rai NS, Mularski RA, Cooper CB, Wise RA, Jones PW, Mehta AC, Gonzalez X, Sterman DH; IBV Valve Trial Research Team.
Wood DE, et al.
J Bronchology Interv Pulmonol. 2014 Oct;21(4):288-97. doi: 10.1097/LBR.0000000000000110.
J Bronchology Interv Pulmonol. 2014.
PMID: 25321447
Clinical Trial.
The primary effectiveness measure was a significant improvement in disease-related quality of life (St. George's Respiratory Questionnaire) and changes in lobar lung volumes. ...Lobar volume changes were significantly different with an average decrease in the treated lobes …
The primary effectiveness measure was a significant improvement in disease-related quality of life (St. George's Respiratory Question …
Item in Clipboard
Cite
Cite